Clinical trial Recruiting at 2 sites Interventional Ages 22 and up

Real-world use of the Rotarex rotational excisional atherectomy device for peripheral arteries

Official title: A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Rotarex(TM) Rotational Excisional Atherectomy System (XTRACT Registry)

Run by C. R. Bard · NCT07016698 · Data updated 2026-11-12

This registry will see if the Rotarex rotational excisional atherectomy device can safely and effectively remove blockages in leg arteries for adults with peripheral arterial disease.

More Peripheral Artery Disease (PAD) trials

Quick facts

Study typeInterventional
Ages22 Years and up
SexAll
Enrollment600 (estimated)
SponsorC. R. Bard
Industry-sponsored
Locations2 sites (Lakeland, Florida and 1 other locations)
StatusRecruiting
StartedSeptember 29, 2025
Main results expectedMarch 31, 2029
Study endsMay 31, 2029
Registry record updatedDecember 17, 2025
Trial IDNCT07016698 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 22 or older with infra-inguinal PAD lesions that can be treated with the Rotarex device per the instructions for use, including chronic limb ischemia (Rutherford 2–5) or selected acute limb ischemia (Rutherford I–IIb) and a guidewire-crossable lesion, are ideal candidates.

Probably not a fit

Patients with vessels under 3 mm in diameter, lesions that cannot be crossed with a guidewire, inability to comply with follow-up, or other contraindications per the device instructions are unlikely to benefit from enrollment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

XTRACT is a prospective, single-arm, multicenter registry enrolling about 600 adults with infra-inguinal peripheral arterial disease treated with the Rotarex rotational excisional atherectomy system according to the device instructions for use. Participants include patients with chronic limb ischemia (Rutherford 2–5) and selected acute limb ischemia (Rutherford I–IIb) whose lesions can be crossed with a guidewire. The registry collects real-world procedural and outcome data across participating centers to characterize device performance and safety. Results will describe procedural success, complications, and mid-term limb outcomes in a broad clinical population.

Why it matters

Potential benefit: If successful, the device could offer a minimally invasive way to clear artery blockages and improve blood flow to the leg, potentially reducing symptoms and the need for more invasive surgery or amputation.

How similar studies have gone: Previous single-center series and smaller registries of the Rotarex device have reported favorable safety and effectiveness for debulking and thrombectomy, and this registry aims to confirm those findings in a larger real-world population.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Subject or legally authorized representative provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the IRB for the site.
2. Subject is ≥22 years old at the time of signing the informed consent.
3. Subject must have a lesion(s) in their infra-inguinal peripheral arteries that can be treated with the RotarexTM Rotational Excisional Atherectomy System according to Instructions For Use (IFU).
4. Rutherford 2-5 for chronic limb ischemia and Rutherford I to IIb for acute limb ischemia.
5. Target lesion can be crossed intra-luminally by guidewire.
6. At least one patent native outflow artery to the foot, free from significant stenosis(≥50% stenosis as confirmed by angiography) (ChLI Cohort only, not applicable to ALI Cohort).

Exclusion Criteria:

1. Subject is unable or unwilling to comply with follow-up procedures and visits.
2. Subject has a target lesion in a vessel with less than 3 mm in diameter.
3. Subject is participating in another device or drug clinical trial that interferes with this protocol and confounds results.
4. Treatment plan includes use of a thrombectomy and/or atherectomy device other than RotarexTM Rotational Excisional Atherectomy System.
5. Life expectancy is below 1 year.
6. Pregnant, planning to become pregnant during the course of the study or nursing a child.

Where it's running

  • Radiology and Imaging Specialists
    Lakeland, Florida, United States
    Recruiting
  • Vital Heart and Vein
    Humble, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Prakash Krishnan, MD, FACC — The Icahn School of Medicine, The Mount Sinai Health System
  • Study coordinator: Adrija Sharma, PhD
  • Email: adrija.sharma@bd.com
  • Phone: 19014578360

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.